Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study

OBJECTIVE: Although modified FOLFIRINOX (mFOLFIRINOX, mFFX) is widely used for patients with advanced pancreatic ductal adenocarcinoma (PDAC), maintenance of the standard dose intensity is often difficult due to the high incidence of neutropenic events. Pegylated granulocyte colony-stimulating facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamao, Kentaro, Takenaka, Mamoru, Yoshikawa, Tomoe, Ishikawa, Rei, Okamoto, Ayana, Yamazaki, Tomohiro, Nakai, Atsushi, Omoto, Shunsuke, Kamata, Ken, Minaga, Kosuke, Hagiwara, Satoru, Sakurai, Toshiharu, Nishida, Naoshi, Chiba, Yasutaka, Watanabe, Tomohiro, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702006/
https://www.ncbi.nlm.nih.gov/pubmed/30996164
http://dx.doi.org/10.2169/internalmedicine.2234-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702006/
https://www.ncbi.nlm.nih.gov/pubmed/30996164
http://dx.doi.org/10.2169/internalmedicine.2234-18

Ejemplares similares